ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Recordati Industria Chimica e Farmaceutica Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.	Italy	REC
RECURSION PHARMACEUTICALS, INC. AI-driven biotech accelerating drug discovery for rare diseases and oncology.	United States of America	RXRX
RedHill Biopharma Ltd. Develops oral drugs for GI, infectious diseases, and pandemic preparedness.	United States of America	RDHL
Regencell Bioscience Holdings Ltd Develops TCM-based therapies for neurocognitive disorders like ADHD and ASD.	United States of America	RGC
REGENERON PHARMACEUTICALS, INC. A biotech firm inventing, developing, and commercializing medicines for serious diseases.	United States of America	REGN
REGENXBIO Inc. Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.	United States of America	RGNX
Rein Therapeutics, Inc. Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.	United States of America	RNTX
Rekah Pharmaceutical Prod Ltd. A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.	Israel	REKA
Relay Therapeutics, Inc. Developing precision medicines for oncology & genetic diseases by analyzing protein motion.	United States of America	RLAY
Repare Therapeutics Inc. Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.	United States of America	RPTX